| scholarly article | Q13442814 |
| P2093 | author name string | Javier Ampuero | |
| Manuel Romero-Gomez | |||
| P2860 | cites work | Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 |
| Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial | Q28253122 | ||
| Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults | Q29614911 | ||
| Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening | Q30277347 | ||
| Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. | Q31049649 | ||
| Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up st | Q36205001 | ||
| Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects | Q37671448 | ||
| Improving Clinical Trial Efficiency: Thinking outside the Box. | Q38389841 | ||
| Treatment of NAFLD with diet, physical activity and exercise. | Q39331043 | ||
| A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis. | Q40082820 | ||
| Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum | Q45064430 | ||
| The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial | Q45067109 | ||
| Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. | Q45070782 | ||
| Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis | Q47394340 | ||
| Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. | Q47765250 | ||
| Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study | Q47956183 | ||
| New therapeutic perspectives in non-alcoholic steatohepatitis | Q50219936 | ||
| NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. | Q51742682 | ||
| Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic. | Q55074201 | ||
| The future R&D landscape in non-alcoholic steatohepatitis (NASH) | Q57036000 | ||
| Master protocol trials in oncology: Review and new trial designs | Q57124868 | ||
| The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity | Q57795277 | ||
| New clinical trial designs in the era of precision medicine | Q64113631 | ||
| Assessment of alcohol consumption in liver transplant candidates and recipients: the best combination of the tools available | Q87586992 | ||
| Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis | Q89138537 | ||
| Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH | Q90138145 | ||
| Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials | Q90474510 | ||
| Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial | Q90566894 | ||
| GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease | Q90612995 | ||
| Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis | Q91484128 | ||
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial | Q91780778 | ||
| Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD | Q91837347 | ||
| Burden of liver diseases in the world | Q91855167 | ||
| Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink? | Q92049257 | ||
| Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial | Q92183751 | ||
| Short- and Long-term Effects of a Mobile Phone App in Conjunction With Brief In-Person Counseling on Physical Activity Among Physically Inactive Women: The mPED Randomized Clinical Trial | Q92268159 | ||
| A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis | Q92322141 | ||
| Placebos and the Placebo Effect in Drug Trials | Q92971181 | ||
| Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations from the Liver Forum | Q94469595 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 100148 | |
| P577 | publication date | 2020-07-21 | |
| P1433 | published in | JHEP Reports | Q96319271 |
| P1476 | title | Stratification of patients in NASH clinical trials: A pitfall for trial success | |
| P478 | volume | 2 |
Search more.